Meeting
2021 ASCO Annual Meeting
LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).
Authors
Maria-Victoria Mateos
Hospital Clínico Universitario de Salamanca/IBSAL/CIC, Salamanca, Spain
Maria-Victoria Mateos , Luděk Pour , Enrique M. Ocio , Pieter Sonneveld , Catarina Jansson Blixt , Kajsa Larsson , Linda Palmér , Paul G. Richardson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04649060
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS8051)
DOI
10.1200/JCO.2021.39.15_suppl.TPS8051
Abstract #
TPS8051
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
First Author: Sagar Lonial
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau
Poster
2021 ASCO Annual Meeting
Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.
First Author: Paula Rodríguez-Otero
Poster
2021 ASCO Annual Meeting
ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results.
First Author: Roman Hajek